Summarized by Masters of Longevity from Longevity Technology.
A biotech partnership announcement about a licensed brain-penetrant enzyme therapy for Parkinson’s, previewing the deal and development roadmap.
Key Takeaways
- Alector granted Genentech exclusive worldwide rights to develop and commercialize AL050.
- AL050 is a brain-penetrant engineered glucocerebrosidase enzyme replacement designed to address GCase deficiency linked to Parkinson’s disease.
